Context Therapeutics Inc. Stock Insider Power

Based on the 81 latest insides trades, we have calculated the insider power to be positive at 97.03. In total, the insiders bought 5 587 087 and sold 1 647 978 CNTX shares in the last 81 trades.

Insider Power

(Last 81 transactions)
97.03
Buy 5 587 087 Shares
Sell 1 647 978 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 13, 2024 Stock Option (right to buy) Buy Stacey Jennifer Evans 25 000
Jun 13, 2024 Stock Option (right to buy) Buy Kantoff Philip W. 25 000
Jun 13, 2024 Stock Option (right to buy) Buy West Linda 25 000
Jun 13, 2024 Stock Option (right to buy) Buy Berman Richard J 50 000
Mar 21, 2024 Stock Option (right to buy) Buy Minai-azary Jennifer Lynn 160 115
Mar 21, 2024 Stock Option (right to buy) Buy Levit Alex C. 153 515
Mar 21, 2024 Stock Option (right to buy) Buy Lehr Martin A. 291 402
May 31, 2023 Stock Option (right to buy) Buy Kantoff Philip W. 25 000
May 31, 2023 Stock Option (right to buy) Buy West Linda 25 000
May 31, 2023 Stock Option (right to buy) Buy Stacey Jennifer Evans 25 000
May 31, 2023 Stock Option (right to buy) Buy Berman Richard J 50 000
Feb 21, 2023 Common Stock Buy Lehr Martin A. 5 823
Feb 13, 2023 Stock Option (right to buy) Buy Levit Alex C. 151 505
Feb 13, 2023 Stock Option (right to buy) Buy Lehr Martin A. 287 544
Feb 13, 2023 Stock Option (right to buy) Buy Minai-azary Jennifer Lynn 158 001
Feb 13, 2023 Common Stock Buy Lehr Martin A. 5 606
Feb 06, 2023 Common Stock Buy Lehr Martin A. 5 040
Jan 30, 2023 Common Stock Buy Lehr Martin A. 7 027
Jan 23, 2023 Common Stock Buy Lehr Martin A. 6 839
Jan 17, 2023 Common Stock Buy Lehr Martin A. 6 783
Dec 16, 2022 Common Stock Buy Minai-azary Jennifer Lynn 25 000
Dec 16, 2022 Common Stock Buy Lehr Martin A. 20 000
Dec 09, 2022 Common Stock Buy Levit Alex C. 6 000
Aug 19, 2022 Common Stock Buy Lehr Martin A. 13 000
Aug 17, 2022 Common Stock Buy Minai-azary Jennifer Lynn 15 000
Click to get the best stock tips daily for free!

About Context Therapeutics Inc.

Context Therapeutics. Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also dev... CNTX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT